Place · Level 3 · Debunking
Magnesium L-Threonate (Magtein)
唯一能进大脑的镁营销学传奇 · 机制基石是 Slutsky 2010 单篇大鼠 / 小鼠论文 · 唯一人体支持是 Liu 2016 N=44 公司资助 RCT · 价格是普通柠檬酸镁的 5-7 倍 · 与 Boyle 2017 系统综述 + NIH ODS 给出的任何形式镁补足缺口都有效一比, 营销叙事 ≫ 证据 · 大多数人该买便宜的镁
Last updated
Story path
- 1What is Mg-L-threonate · the Magtein storyWhat is Mg-L-threonate · the Magtein story
- 2Marketing claim · three layersMarketing claim · three layers
- 3Slutsky 2010 · the animal paper as foundationSlutsky 2010 · the animal paper as foundation
- 4Liu 2016 · N=44 · company-funded · sole RCTLiu 2016 · N=44 · company-funded · sole RCT
- 5Decision tree · most people should buy other MgDecision tree · most people should buy other Mg
Chapter 1
What is Mg-L-threonate · the Magtein story
What is Mg-L-threonate · the Magtein story
Magnesium L-Threonate (Mg-L-T) is a magnesium salt — elemental magnesium chelated with L-threonic acid. L-threonic acid is itself a metabolite of ascorbic acid (vitamin C), produced via oxidation/degradation in vivo. So at the molecular level, magnesium L-threonate = 'magnesium + a vitamin C metabolite' — which by itself carries no special pharmacological meaning. It is just a salt.
There is no real chemical or regulatory controversy here: it is GRAS, has a clean safety profile, no hepatorenal toxicity and no notable drug interactions. What we are debunking is not 'whether this is magnesium' — it is. What we are debunking is 'whether it is worth 5× the price of other magnesium forms', which is a marketing claim. The next four scenes peel that claim back layer by layer.
There is no real chemical or regulatory controversy here: it is GRAS, has a clean safety profile, no hepatorenal toxicity and no notable drug interactions. What we are debunking is not 'whether this is magnesium' — it is. What we are debunking is 'whether it is worth 5× the price of other magnesium forms', which is a marketing claim. The next four scenes peel that claim back layer by layer.
Brand history · MIT lab to Magtein™
The reason this compound became a supplement-market star is almost entirely the marketing narrative:In 2010, MIT neuroscientist Guosong Liu (also affiliated with Tsinghua), working with Susumu Tonegawa's lab, published the Slutsky 2010 paper in Neuron suggesting that this particular magnesium salt could raise rat/mouse cerebrospinal-fluid (CSF) magnesium and improve learning/memory task performance.That same year Liu and his team founded Magceutics, with U.S. distribution later picked up by AIDP (a California ingredient company), and the patented molecule was registered as the Magtein™ brand.From 2012 onward, AIDP licensed Magtein™ to dozens of supplement brands in the U.S., Europe and China (Life Extension, Pure Encapsulations, Jarrow, Doctor's Best, Now Foods and many others all carry a Magtein version).During 2020–2024, riding the Huberman / Joe Rogan / TikTok 'sleep / anxiety / memory' wave, 50+ Magtein products appeared in the U.S. market, priced at USD 30–60 per month — roughly 5–7× the cost of an equivalent elemental dose from magnesium citrate or glycinate.
化学 · 盐一进身体就散架了
把镁盐想成一辆车加一位乘客: 苏糖酸是车, 镁离子是乘客。而下车的地点在肠道, 不在大脑。镁盐在水里会解离——这是所有盐共有的行为, 不是苏糖酸镁的特例。你吞下的胶囊在胃液和肠液里溶开之后, 镁离子和苏糖酸就各走各的:
镁离子被肠壁上的通道蛋白拉进肠细胞, 或者顺着细胞之间的缝隙渗过去。那些通道认的是带正电、外面裹着一层水分子的镁离子本身, 不认它刚才配着哪个阴离子。苏糖酸是抗坏血酸 (维生素 C) 降解链上的一个小分子酸, 身体本来就有处理它的路子——这正是这个盐安全的原因, 也是它没有额外故事可讲的原因。
进了血液之后, 镁的存在形式在生理学里描述得很清楚: 大部分是游离的镁离子, 一部分挂在白蛋白上被拎着走, 还有一小部分和血里的阴离子结合成松散的复合物。血浆镁不是一堆苏糖酸镁分子在血里漂, 它是一池离子。
所以形式能起作用的窗口只有一段: 从嘴到肠壁。 过了这一段, 无论你吞下去的是氧化镁、柠檬酸镁还是苏糖酸镁, 血里流的都是同一种东西——镁离子。一个形式想在大脑那一端还保有特殊性, 它必须先证明自己走完这一段之后还是一个完整的分子, 而不是散成了一堆离子。这一步, 营销叙事从来没有面对过。
Chapter 2
Marketing claim · three layers
Marketing claim · three layers
Peel the magnesium L-threonate marketing into three layers, each requiring its own validation.
Layer 1 (consumer-facing slogan): 'the only magnesium that gets into the brain' / 'the magnesium for ADHD, anxiety, Alzheimer, insomnia' / '+25% memory in 12 weeks' / 'synapse density enhancer'. This kind of language appears on the Magtein brand site, on dozens of supplement product pages, and is the version chanted in KOL videos.
Layer 2 (evidence the brand cites): nearly every slogan traces back to two papers — the animal study Slutsky 2010 (Neuron) and the single human RCT Liu 2016 (Journal of Alzheimer's Disease, also known as the MMFS-01 trial). Liu Guosong is the corresponding author on both, and is also the Magtein patent holder and Magceutics founder. The brand additionally lists a long bibliography of 'related' in vitro experiments and aged-rat-model papers, but those do not constitute direct support for human claims.
Layer 1 (consumer-facing slogan): 'the only magnesium that gets into the brain' / 'the magnesium for ADHD, anxiety, Alzheimer, insomnia' / '+25% memory in 12 weeks' / 'synapse density enhancer'. This kind of language appears on the Magtein brand site, on dozens of supplement product pages, and is the version chanted in KOL videos.
Layer 2 (evidence the brand cites): nearly every slogan traces back to two papers — the animal study Slutsky 2010 (Neuron) and the single human RCT Liu 2016 (Journal of Alzheimer's Disease, also known as the MMFS-01 trial). Liu Guosong is the corresponding author on both, and is also the Magtein patent holder and Magceutics founder. The brand additionally lists a long bibliography of 'related' in vitro experiments and aged-rat-model papers, but those do not constitute direct support for human claims.
Layer 3 · actual physiology
Layer 3 (the actual scientific background): this is where it matters. Adult plasma magnesium sits around 0.75–0.95 mmol/L, cerebrospinal fluid magnesium around 1.0–1.2 mmol/L. All forms of oral magnesium — oxide, citrate, glycinate, chloride — when they raise plasma magnesium after correcting a deficit, also raise CSF magnesium via the TRPM7 / MagT1 transporters at the blood-brain barrier (the de Baaij 2015 Physiological Reviews paper lays out the full physiology). There is no form of magnesium that 'rises in plasma but stays out of the brain', and no form that 'bypasses the blood-brain barrier and goes straight to the brain'. The marketing concept 'the magnesium that gets into the brain' is not a meaningful physiological distinction — the implied contrast ('other magnesium can't reach the brain') is simply false.This is the core problem with Magtein marketing: between Layer 1 (what lay readers hear) and Layer 3 (the actual physiology) sits a very thin shell built on two papers. The next two scenes pressure-test exactly those two papers.
机制 · 镁进了脑, 到底在干什么
营销说能进大脑, 生理学说每种镁都进得去——但两边都没说清一件事: 镁进去之后到底在干什么。 不知道它干什么, 能不能进脑就只是一句口号。脑子里最主要的兴奋信号是谷氨酸 (glutamate)。它停靠在神经元表面的受体上, 打开通道, 让带正电的离子涌进细胞, 神经元被点着。其中一类通道叫 NMDA 受体, 你可以把它读成要两个条件同时成立才肯开的那一种。
它平时堵着一个镁离子。这个塞子的妙处在于它是看电压的: 细胞内侧带负电, 把带正电的镁往孔里吸, 于是塞得很牢。只有当这个神经元已经被别的信号先激活、内侧的负电被抵消掉一部分, 吸力才松开, 镁被挤出去, 通道这才真正通开。
于是: NMDA 受体只在谷氨酸来了并且这个神经元本来就在兴奋两件事同时成立时才放行。它是一个符合检测器, 而那个镁塞子就是门槛本身。镁不够时: 任何时刻塞着的孔变少, 门槛往下掉, 同样一份谷氨酸更容易把神经元点着。成千上万个突触同时如此, 外在的体感就是熟悉的那几样——身体绷着松不下来、思绪停不住、躺下之后脑子还在转、对声音和光更敏感。补足缺口 = 把塞子放回去。 而塞子不认它是从哪种盐来的: 卡在孔里的是一个带正电的镁离子, 苏糖酸早在肠道那一段就和它分开了。
补上这一环, 这篇文章的核心论点就不必再靠引权威撑着: 任何形式的镁, 只要把身体里的镁补回来, 塞子就回得去。 一个形式想比别的强, 它必须在塞子这一端做出不一样的事, 而不是在进不进得去这一端喊得更响。
数字 · 脑脊液的镁本来就比血里高
有一件事很容易滑过去: 脑脊液的镁比血浆更高。 这个方向本身就值得停一下——如果只是被动渗透, 两边应该趋于相等才对。脑脊液不是血漏进颅腔的水, 它是脉络丛这层组织造出来的。脉络丛的细胞排在脑室的内壁上, 一边从血里挑东西搬进来, 一边把不该进的挡在外面; 脑脊液的成分因此是被主动定标的, 而不是被动跟着血走。镁被定在比血浆更高的位置上, 说明身体在优先保住脑子里的这一份。
这件事有两个后果, 都正对着营销叙事:
正常情况下, 脑不是一个缺镁的器官。 身体宁可从骨头和肌肉里挪, 也要先把这一池守住。所以一个针对脑镁不够的高价解法, 首先得回答脑什么时候才真的不够——答案是: 在全身镁本来就有缺口的时候。而那正好是任何一种镁都能解决的情形。脑脊液镁是浴缸的水位, 不是水龙头的出水量。 它测的是泡着神经元的那池液体, 不是某个突触在那一刻发生了什么, 更不是塞子有没有回到通道口。一个动物实验测到这池水位抬高了, 离这只动物记得更牢还隔着好几步, 离你会更聪明隔得更远。
Chapter 3
Slutsky 2010 · the animal paper as foundation
Slutsky 2010 · the animal paper as foundation
Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Li B, Zhao X, Govindarajan A, Zhao MG, Zhuo M, Tonegawa S, Liu G. (2010). *Enhancement of learning and memory by elevating brain magnesium.* Neuron 65(2): 165–177. This is the 'mechanistic foundation' of the entire Magtein marketing story — and it is a textbook early-stage animal study, nowhere near able to hold up the human claims the brand stacks on top of it.
What the paper did:
Administered various magnesium salts (oxide, citrate, L-threonate) orally or by injection to rats and mice, then measured plasma and cerebrospinal-fluid (CSF) magnesium changes.Reported that animals on Mg-L-threonate showed larger CSF magnesium increases than animals on equivalent elemental doses of magnesium oxide or citrate.Hippocampal slices showed increased NR2B-subunit NMDA-receptor expression and synaptic density.Behavioral assays (Morris water maze, object recognition) showed faster learning in the Mg-L-T group.
What the paper did:
Administered various magnesium salts (oxide, citrate, L-threonate) orally or by injection to rats and mice, then measured plasma and cerebrospinal-fluid (CSF) magnesium changes.Reported that animals on Mg-L-threonate showed larger CSF magnesium increases than animals on equivalent elemental doses of magnesium oxide or citrate.Hippocampal slices showed increased NR2B-subunit NMDA-receptor expression and synaptic density.Behavioral assays (Morris water maze, object recognition) showed faster learning in the Mg-L-T group.
Methodological gaps · six standard red flags
Standard methodological limitations any biomedical-methods course would flag:Species: rodents ≠ humans, with differences in magnesium metabolism, intestinal absorption, and blood-brain-barrier transporter expression.Sample size: the typical small N of an animal study — exploratory, not designed to underwrite human conclusions.Controls: dose-equivalent comparators for high-absorption forms like magnesium citrate or glycinate were not fully matched; marketing language has spun this into 'other magnesium absorbs poorly', which overreaches what the paper shows.Replication: 14 years on, there is no independent replication from labs unaffiliated with Liu's team and not funded by Magceutics.Endpoints: hippocampal NR2B upregulation + better water-maze performance are easy-to-hit endpoints in rodents; they are not human 'memory improvement' and certainly not human 'Alzheimer prevention'.Conflicts of interest: the corresponding author Liu Guosong is also the Magtein patent holder and later the founder of Magceutics/Magtein. The disclosure is in the paper, but readers should treat it as the 'founding paper' of a commercial product line.
What it supports · what it doesn't
What it can support: in rodents, magnesium L-threonate is an interesting tool compound that, under specific conditions, can raise CSF magnesium higher than magnesium oxide does (in animals).What it cannot support: 'the only magnesium that gets into the human brain' / 'improves memory in humans' / 'prevents Alzheimer'. Those extrapolations cross species, clinical endpoints and disease categories, and a single 14-year-old animal paper cannot carry that weight. The next scene examines the one human RCT Liu's group itself ran.
机制 · 一扇新门, 还是同一扇门上多了车流
这篇动物论文报告的核心事实只有一条: 给苏糖酸镁的动物, 脑脊液里的镁比给同等元素镁的氧化镁 / 柠檬酸镁的动物升得更高。这条事实有两种完全不同的读法, 而营销只讲了其中一种。读法一 · 一扇新门 (营销的版本)。 苏糖酸把镁护送过血脑屏障, 走的是别的镁走不了的路。要让这个读法成立, 至少得同时满足两件事:
这个复合物在肠道和血液里一直没散, 保持完整的分子形态抵达脑血管;血脑屏障上存在一个认这个复合物的搬运工, 而不只是那些认镁离子本身的通道。
已发表的镁生理学描述的是后者: 镁跨膜靠的是认离子的孔——孔的口径和电荷分布是照着外面裹着水的镁离子长的, 不是照着一个镁配着有机酸的复合物长的。想让第一种读法成立, 得先有人把那个认复合物的搬运工拿出来。
读法二 · 同一扇门, 车流大了一点。 苏糖酸镁在肠道那一段吸收得多一点, 或者在血里停留得久一点, 于是血浆镁的曲线更高更平; 血浆镁高了, 顺着同一批转运体进脑的量自然也跟着多。这个读法不需要任何新机制, 只需要吸收动力学有点差别——而不同镁盐吸收有差别, 本来就是已知的事。
两种读法怎么分辨? 分辨点很具体: 如果是同一扇门, 那么把对照组的血浆镁曲线拉到和苏糖酸镁组一样高, 脑脊液的差距就该消失; 如果真是一扇新门, 差距会留下来。这正是一个独立实验室会去做的实验——而它没有被做。
在这个分辨做出来之前, 唯一能进大脑的镁缺的不是样本量, 是机制上的可能性还没有被建立。
读动物论文 · 剂量和给药方式为什么不能照搬
论文正文里那句口服或注射很容易滑过去, 但它是这篇论文和你手里那瓶胶囊之间最大的一道裂缝。注射绕开了整条肠道。 而肠道恰恰是形式唯一有机会起作用的那一段: 镁从哪种盐来、吸收多少、吸收多快, 全在这一段决定。一个把肠道跳过去的实验, 结果再漂亮也说不了吞下去会怎样。
动物身上每公斤给多少, 也不能照着乘自己的体重。 体型越小的动物, 单位体重的代谢速度越快: 同样每公斤给一份, 小动物清除得更快, 血里的浓度曲线形状也不一样。所以把动物剂量折算到人, 通行做法是按体表面积换算而不是按体重, 折算之后人的每公斤剂量总是明显小于动物的那一份。看到一个动物研究的每公斤剂量就直接乘上自己的体重, 是补剂宣传里最常见的一种越界。
还有一层最容易被跳过: 读任何补充剂的动物实验都要先问一句——这些动物本来缺不缺? 一个不缺的个体再加一份, 测的是加更多会怎样; 而你这一端的真实问题是我本来就有缺口, 补回来会怎样。这是两个不同的问题, 答案可以完全不同。这篇文章反复回到的那句补足缺口, 说的正是后一个。
Chapter 4
Liu 2016 · N=44 · company-funded · sole RCT
Liu 2016 · N=44 · company-funded · sole RCT
Liu G, Weinger JG, Lu ZL, Xue F, Sadeghpour S. (2016). *Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial.* Journal of Alzheimer's Disease 49(4): 971–990. This is the human evidence the brand cites most often, and so far the only RCT testing Magtein on cognitive endpoints.
Trial design:
Subjects: adults aged 50–70 with subjective memory complaints but not meeting dementia criteria, recruited in Southern California.Sample: 44 randomized (about 51 enrolled with some dropout), allocated to MMFS-01 (i.e. magnesium L-threonate) at 1.5–2 g/day or placebo.Duration: 12 weeks.Endpoints: a composite cognitive score combining four domains (attention / working memory / executive / episodic memory), plus several secondary tests.
Reported main results: the treatment group showed larger gains on the composite score than placebo; on a 'cognitive age' estimate the group appeared to walk back about 9 years. These numbers are reproduced on Magtein product pages over and over.
Trial design:
Subjects: adults aged 50–70 with subjective memory complaints but not meeting dementia criteria, recruited in Southern California.Sample: 44 randomized (about 51 enrolled with some dropout), allocated to MMFS-01 (i.e. magnesium L-threonate) at 1.5–2 g/day or placebo.Duration: 12 weeks.Endpoints: a composite cognitive score combining four domains (attention / working memory / executive / episodic memory), plus several secondary tests.
Reported main results: the treatment group showed larger gains on the composite score than placebo; on a 'cognitive age' estimate the group appeared to walk back about 9 years. These numbers are reproduced on Magtein product pages over and over.
Six methodological flaws
Serious limitations of this RCT:Sample: N = 44 in a cognitive intervention study is exploratory pilot territory, not a confirmatory trial. By comparison, the FINGER trial of older-adult cognition had N = 1260; PREDIMED on the Mediterranean diet had N = 7447. The size gap on that one axis alone is 30–150×.Duration: 12 weeks is extremely short relative to the timescale of cognitive decline itself (5–20 years).Funding: the trial was funded by Magceutics. Corresponding author Liu Guosong is the founder of Magceutics, the patent holder for Magtein, and the inventor of MMFS-01, the very test article. In a drug RCT, that level of overlap would normally trigger strict independent oversight or third-party analysis; the supplement market imposes no such constraint.Endpoint design: the primary endpoint is a weighted composite of four subtests. Composite primary endpoints leave a lot of room for the analyst — if any sub-component nudges past significance, the composite can drag the overall result across the line. Modern clinical trials increasingly require preregistration with pre-specified sub-endpoint analyses; this paper is not transparent on that front.The four measured sub-domains: attention improved significantly, but executive / working memory / episodic memory did not all independently cross significance. Slogans like '+25% memory' and 'cognitive age −9 years' depend almost entirely on post hoc selection of the favorable cut.Replication: 8 years on, no independent (non-Magceutics-funded, non-Liu-led) RCT has reproduced these numbers. A single small-sample trial is universally regarded in biomedicine as 'worth a larger follow-up study', not as 'fit for product marketing'.
Cross-comparison · narrative ≫ evidence
Cross-comparison makes the scale gap clearer:Boyle 2017 (Nutrients) systematic review on magnesium supplementation for subjective anxiety and stress pools multiple RCTs (hundreds of participants) at B-tier evidence — any form of magnesium has a mild positive effect on anxiety and subjective stress when intake is deficient, and no included study showed L-threonate outperforming citrate or glycinate.de Baaij 2015 (Physiological Reviews), the authoritative magnesium-physiology review, attributes every known cognitive and mood signal of magnesium to 'correcting a deficit', not to a specific salt form.NIH ODS 2022 magnesium professional fact sheet likewise makes no recommendation favoring Mg-L-T over any other form.
Bottom line: Liu 2016 is not the apex of the Magtein evidence story — it is the entire evidence story. N = 44 + company funding + founder as corresponding author + composite endpoint + no independent replication: any single item is survivable, but stacked together this paper cannot bear the scientific weight of an entire supplement subcategory.
Chapter 5
Decision tree · most people should buy other Mg
Decision tree · most people should buy other Mg
Reduce the whole thing to 'how should I spend $30 from my wallet'.
Background first: U.S. NHANES data estimate ~50% of adults fall below the magnesium RDA. Chinese CHNS data put it close to half as well. So most people topping up magnesium has real meaning — but that is a different question from 'which magnesium'.
RDA (NIH ODS): men 19–30 400 mg / men 31+ 420 mg / women 19–30 310 mg / women 31+ 320 mg / pregnancy +40 mg.
Priority 1 (food): leafy greens (1 cup cooked spinach = 78 mg) / pumpkin seeds (1 oz = 156 mg) / almonds (1 oz = 80 mg) / black beans (1 cup cooked = 120 mg) / whole grains (1 cup brown rice = 85 mg) / dark chocolate 70%+ (1 oz = 64 mg). Someone who eats greens, nuts and whole grains can meet the daily RDA from food alone — in which case this box is closed and no supplement is required.
Background first: U.S. NHANES data estimate ~50% of adults fall below the magnesium RDA. Chinese CHNS data put it close to half as well. So most people topping up magnesium has real meaning — but that is a different question from 'which magnesium'.
RDA (NIH ODS): men 19–30 400 mg / men 31+ 420 mg / women 19–30 310 mg / women 31+ 320 mg / pregnancy +40 mg.
Priority 1 (food): leafy greens (1 cup cooked spinach = 78 mg) / pumpkin seeds (1 oz = 156 mg) / almonds (1 oz = 80 mg) / black beans (1 cup cooked = 120 mg) / whole grains (1 cup brown rice = 85 mg) / dark chocolate 70%+ (1 oz = 64 mg). Someone who eats greens, nuts and whole grains can meet the daily RDA from food alone — in which case this box is closed and no supplement is required.
Supplement choice · cheap Mg vs Magtein premium
Priority 2 (ordinary magnesium supplement, when food doesn't fill the gap): not complicated.Magnesium citrate: high absorption, GI-friendly, cheap (about USD 5–10 per month for 200 mg elemental Mg/day). The pragmatic first pick for most people.Magnesium glycinate / bisglycinate: slightly better observational signal on sleep and anxiety, very little GI upset, suits evening dosing, USD 8–15 per month.Magnesium chloride / lactate: also fine, well absorbed.Avoid magnesium oxide as a standalone (poor absorption — fine as one component of a blended formula).
Priority 3 (magnesium L-threonate / Magtein): USD 30–60 per month. 5–7× more expensive than Priority 2. It is genuinely magnesium, it is safe, and there is no ethical concern about it — we are not calling it harmful. What we are saying is that no A- or B-tier evidence shows it outperforms magnesium citrate at the actual job of correcting a magnesium deficit. Slutsky 2010 is an animal paper, Liu 2016 is an N=44 company-funded single RCT — both are C-tier evidence.
Are you willing to pay an extra USD 25–50 per month for 'maybe a small extra cognitive boost that has not been independently replicated in 8 years'? This is a real wallet question with no universal answer — but understand that what you are buying is a 'C-tier-evidence premium', not 'a smarter magnesium'.
Actually protect cognition · A-tier spending
When you genuinely want to invest in cognitive health, spending the same budget and time in any of these directions beats Magtein:150 minutes/week of moderate aerobic exercise + 2 strength sessions (A-tier, FINGER and multiple meta-analyses).7–9 hours of sleep per night (A-/B-tier, multiple prospective cohorts).Mediterranean / DASH / MIND eating pattern (A-tier, PREDIMED, FINGER).Weekly deep contact with friends / family (A-tier, UK Biobank and Harvard Adult Development Study).Hearing screening and using a hearing aid when indicated (one of the largest modifiable factors in the Lancet 2024 dementia commission report).Controlling blood pressure / glucose, and not smoking (A-tier).
This is not a scam alert: Magtein is real magnesium, safe, and in a person who has a magnesium deficit it does close that deficit — just as magnesium citrate does. The problem is the distance between the marketing narrative and the evidence: 'the only magnesium that gets into the brain' is wrong, and '5× smarter than other magnesium' has no evidence.
One-sentence summary:
> Magnesium L-threonate is magnesium, not magic. Most people have a magnesium gap — close it first with food, then cheap forms (citrate or glycinate); paying 5× for Magtein buys a premium on the marketing claim, not a better brain.
>
> If you really want to protect cognition, take those USD 25–50 of monthly difference and spend them on gym, better food, or sleep-environment upgrades. Those are A-tier evidence; Magtein is C-tier.
机制 · 为什么更强的镁这个想法本身有天花板
退一万步: 假设苏糖酸镁真的能把脑里的镁推得比别的镁更高——就算这一步白送给它, 更高也不自动等于更好, 因为它作用的那个位置是会坐满的。镁在神经元这一端干的活是堵住通道口, 把兴奋门槛顶住。通道口的数量是固定的: 该堵的都堵上之后, 再多的镁没有新的孔可以去堵。这类位点有限的机制, 剂量效应天然是一条先陡后平的曲线——缺口那一段每补一点都有回报, 补齐之后曲线就躺平了。
身体还在两头替你踩刹车:
肠道这一头: 镁的主动吸收通道会被填满。剂量越大, 靠通道进来的比例越低, 多出来的那部分只能顺着细胞之间的缝隙慢慢渗——于是吃得越多, 吸收率反而越低。真吃过量的人最先遇到的也不是效果更强, 而是跑厕所: 留在肠腔里没被吸走的镁把水一起拽着往下走。肾脏那一头: 肾小管会把滤出去的镁重新吸收回来, 但超过它的处理能力, 多余的镁就直接随尿走了。血浆镁因此被按在一个很窄的区间里, 不会因为你多吃就一路往上爬。
把这三件事放在一起, 一种能把镁推得更高的镁这个卖点就漏了底: 门槛机制会饱和, 肠道会限流, 肾脏会放水。真正决定你有没有好处的, 是你原来的缺口有多大, 不是载体有多花哨。这也是为什么横向对比里那几篇综述会给出同一个结论——不是它们互相抄, 是机制本来就长这样。
References · 5
- National Institutes of Health, Office of Dietary Supplements. (2022). Magnesium — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/Magnesium-HealthProfessional
- de Baaij, J. H. F., Hoenderop, J. G. J., & Bindels, R. J. M. (2015). Magnesium in man: implications for health and disease. Physiological Reviews, 95(1), 1–46. 10.1152/physrev.00012.2014
- Slutsky, I., Abumaria, N., Wu, L.-J., Huang, C., Zhang, L., Li, B., Zhao, X., Govindarajan, A., Zhao, M.-G., Zhuo, M., Tonegawa, S., & Liu, G. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. 10.1016/j.neuron.2009.12.026
- Liu, G., Weinger, J. G., Lu, Z.-L., Xue, F., & Sadeghpour, S. (2016). Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. Journal of Alzheimer's Disease, 49(4), 971–990. 10.3233/JAD-150538
- Boyle, N. B., Lawton, C., & Dye, L. (2017). The effects of magnesium supplementation on subjective anxiety and stress — a systematic review. Nutrients, 9(5), 429. 10.3390/nu9050429